Filed: 5/9/2025ACC: 0001843547-25-000007
📋 What this filing means
VANTAGE CONSULTING GROUP INC filed this quarterly 13F‑HR report disclosing 4 equity positions with a total reported market value of $5.02M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
4
Positions
$5.02M
Total AUM (reported)
4.61M
Total Shares
Allocation by class
COM$5.02M100.0%
Portfolio Concentration
Top 3$4.96M98.8%
4–10$60.6K1.2%
Top 3 weight
98.8%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 4.61M
Sole
Full voting authority
4.61M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole4
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings4
Rows:
Cibus, Inc.
SOLEShares1.14M
TypeSH
Market value$2.14M
42.58%
Sole
1.14M
Shared
0.00
None
0.00
Babcock & Wilcox Enterprises Inc.
SOLEShares2.42M
TypeSH
Market value$1.62M
32.34%
Sole
2.42M
Shared
0.00
None
0.00
ADC Therapeutics SA
SOLEShares850.74K
TypeSH
Market value$1.20M
23.88%
Sole
850.74K
Shared
0.00
None
0.00
Fibrogen, Inc
SOLEShares195.71K
TypeSH
Market value$60.6K
1.21%
Sole
195.71K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Cibus, Inc.SOLE | COM | 1.14M | SH | $2.14M 42.58% | 1.14M | 0.00 | 0.00 |
Babcock & Wilcox Enterprises Inc.SOLE | COM | 2.42M | SH | $1.62M 32.34% | 2.42M | 0.00 | 0.00 |
ADC Therapeutics SASOLE | COM | 850.74K | SH | $1.20M 23.88% | 850.74K | 0.00 | 0.00 |
Fibrogen, IncSOLE | COM | 195.71K | SH | $60.6K 1.21% | 195.71K | 0.00 | 0.00 |